US-based Aceto has finished its 2013 first quarter with a net income of $4.8m compared to a prior year figure of $3m. At the same time, net sales rose 10.3 per cent year-on-year from $101.3m to $111.7m. "We are very pleased with our results for the first quarter of fiscal 2013. Total company sales were up 10.3 per cent. Our Human Health segment continues to show strength with a sales increase of 16.1 per cent, largely driven by new generic product launches in our Rising Pharmaceuticals subsidiary. Performance Chemicals also showed a significant increase as strong demand for agricultural products led a 23.4 per cent revenue increase in the quarter," says chairman and CEO Albert Eilender.
展开▼
